Evidence map›Paper›PMID 41875078›Full record

ArticlePLoS biology2026

A quantitative cell-based reporter links TDP-43 aggregation and dysfunction to define pathogenic mechanisms.

Lohany Dias Mamede, Miwei Hu, Jaime Vaquer-Alicea, Amanda R Titus, Patricia M Passos, Erica Lantelme, Rachel L French, Paige A Kirschner, Marc I Diamond, Timothy M Miller and 1 more

Abstract read
In one paragraph

Article in PLoS biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Lohany Dias MamedeEdward Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.
Miwei HuDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Jaime Vaquer-AliceaCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, Texas, United States of America.
Amanda R TitusEdward Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.
Patricia M PassosEdward Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.
Erica LantelmeDepartment of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States of America.
Rachel L FrenchAgilent Technologies, Santa Clara, California, United States of America.
Paige A KirschnerDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Marc I DiamondCenter for Alzheimer's and Neurodegenerative Diseases, Peter O'Donnell Jr. Brain Institute, UT Southwestern Medical Center, Dallas, Texas, United States of America.
Timothy M MillerDepartment of Neurology, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Yuna M AyalaEdward Doisy Department of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI Susan Lynn Stark · 2020 to 2026
$28.7M
Training Program in Cellular and Molecular BiologyT32GM139774 · NIGMS · WASHINGTON UNIVERSITY · PI HEATHER L TRUE-KROB · 2021 to 2026
$6.7M
Neuroscience Training Program at Washington UniversityT32NS121881 · NINDS · WASHINGTON UNIVERSITY · PI Martha W Bagnall, Daniel Kerschensteiner · 2021 to 2026
$3.1M
Role of oligomeric TDP-43 aggregate intermediates in ALS and frontotemporal dementiaR01NS114289 · NINDS · SAINT LOUIS UNIVERSITY · PI AYALA, YUNA · 2020 to 2024
$1.9M
NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIGMS NIH HHS T32 GM139774NINDS NIH HHS R01 NS114289NINDS NIH HHS T32 NS121881
6 · The paper itself

Abstract

TDP-43 pathology is a hallmark of fatal neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43-encephalopathy (LATE). In affected patients, cytoplasmic TDP-43 aggregates are accompanied by disruption of its normal nuclear localization and function. Because TDP-43 is an RNA binding protein that controls transcript processing, including repression of cryptic exon splicing, its loss leads to dysregulation of gene expression. Despite its central significance in disease, the connection between TDP-43 aggregation and dysfunction remains poorly understood, and models to study the underlying mechanisms are limited. Here, we characterize a robust and quantitative cell-based reporter that captures both aggregation and the resulting loss of function. Using this human biosensor cell line, we show that aggregation initiated by prion-like seeding drives progressive depletion of nuclear TDP-43 and induces signature features of diminished TDP-43 activity, such as increased DNA damage and activation of cryptic exon splicing. We find that aggregate seeding also induces cryptic exon splicing in human neurons implying that this pathological link extends to disease-relevant models. The seeding model provides a platform for dissecting mechanisms that underlie TDP-43 pathology and for identifying factors that modulate the aggregation-to-dysfunction transition. Our data shows that aggregate seeding impacts TDP-43 autoregulation, initiating a toxic feed-forward mechanism that disrupts TDP-43 homeostasis. Furthermore, reducing ataxin-2 levels decreases aggregation and restores TDP-43 activity. Together, these findings reveal a molecularly guided strategy to directly impact TDP-43 activity by decreasing its misfolding and aggregation, highlighting approaches to prevent TDP-43 dysfunction and mitigate toxicity under pathological conditions.

Indexed as

DNA-Binding ProteinsProtein Aggregation, PathologicalCell LineCell NucleusDNA DamageExonsGenes, ReporterHumansNeuronsProtein AggregatesRNA SplicingTDP-43 ProteinopathiesDNA-Binding ProteinsProtein AggregatesTARDBP protein, human

Identifiers

PMID41875078
PMCPMC13012477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.